GI Clinical Trialists Bootcamp

Interested in learning more about clinical trials and how you can become involved?

Join our 10-week bootcamp for GIs interested in becoming clinical trial investigators or simply learning more about clinical trials. Clinicians who identify with a group underrepresented in medicine (URiM), who treat URiM patients, or who practice in an area with limited access to clinical trial sites are highly encouraged to apply for this free, CME-accredited program. 

We’re diversifying clinical trials from the top down.

Our goal is to increase the number and diversity of gastroenterologists involved in clinical trials and ultimately increase the participation of underrepresented or underserved patients in clinical trials. Bootcamp participants will join an exclusive cohort with access to virtual and on-demand sessions taught by leading experts in IBD clinical trials. Bootcamp graduates will be eligible for travel grants to visit an established clinical trial site. Our next cohort will focus on clinical trials in inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease. 

Application due date

Applications for the GI Clinical Trialists Bootcamp are due by
November 18, 2022.

Selected participants will be notified in December 2022 and will begin with a kickoff at the Crohn’s and Colitis Congress in January 2023. 

The GI Clinical Trialist Bootcamp is part of a larger AGA initiative to strengthen, diversify and connect the clinical trials workforce within gastroenterology. We are starting with a focus on IBD clinical trials due to the increasing challenges of recruiting diverse patients, particularly in the U.S.  

This free, 10-week training program includes comprehensive training for gastroenterologists through live virtual and on-demand education. The cohort will be limited to 25 participants to maximize interactions with program faculty and your fellow participants. The curriculum covers key issues in clinical trial investigation, including but not limited to investigator responsibilities, regulatory requirements, clinical trial operations, protocol development, informed consent and medical ethics. 

Participants will also have access to travel grants supporting a site visit to an established clinical trial site to observe their operations and meet with an established IBD clinical trialist and their clinical research staff. Should in-person interaction not be possible, AGA will facilitate virtual interactions between the participant and the established clinical trial site. 

Twenty-five individuals will be selected to participate in this program. AGA membership is not required to apply for this program. Additional requirements may be found below: 

Applicants must be physicians who treat IBD, from any type of practice, who fulfill at least one of the following criteria: 

  • Identify with a racial and/or ethnic group that is underrepresented in medicine (URiM): African Americans or Blacks, Native Alaskans, Native Americans, U.S. Pacific Islanders and individuals of Hispanic origin.
  • Serve a diverse patient population, particularly patients who identify with URiM racial and/or ethnic groups.  
  • Work in a practice setting with little to no existing infrastructure for clinical trials. 
  • Practice in a geographic area without easy access to established clinical trial sites. 

Steering Committee

Maria T. Abreu, MD, AGAF

Maria T. Abreu, MD, AGAF

University of Miami Miller School of Medicine 

Anita Afzali, MD, MPH, MHCM, FACG, AGAF

Anita Afzali, MD, MPH, MHCM, FACG, AGAF

The Ohio State University Wexner Medical Center

Leonard K. Baidoo, MD, FACG, AGAF

Leonard K. Baidoo, MD, FACG, AGAF

University of Tennessee Health Science Center

Brigid S. Boland, MD

Brigid S. Boland, MD

University of California, San Diego

Adam S. Cheifetz, MD

Adam S. Cheifetz, MD

Beth Israel Deaconess Medical Center

Andres J. Yarur, MD

Andres J. Yarur, MD

Cedar-Sinai Medical Center 

This program is supported by an educational grant from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.